Vienna-based Nyra Health has secured €20 million in Series A funding to scale its multimodal neurotherapy platform. The round was led by Armira Growth, with participation from Wellington Partners and EVER Pharma, as the company prepares to expand its clinical footprint across Europe and the United States.
The big picture: Neurological disorders like stroke and dementia place a massive structural burden on aging healthcare systems, often resulting in a “rehabilitation cliff” once patients are discharged from inpatient care. Nyra Health bridges this gap with its myReha platform, an MDR Class IIa-certified medical device that uses AI to provide adaptive speech, cognitive, and motor therapy at home.
How it works:
- Multimodal Analysis: Analyzes speech patterns, reaction times, and error profiles to dynamically adjust therapy intensity and tasks.
- Clinical Integration: The “Nyra Insights” system allows therapists to monitor progress and automate documentation in real-time.
- Proven Outcomes: Integrated into the German Pension Insurance (DRV) framework, the platform is already reimbursed by over 28 insurers for more than 40 million individuals.
The catch: While digital therapeutics (DTx) offer a scalable solution for chronic care, the geriatric population—the primary demographic for neurorehabilitation—often faces the highest barriers to technology adoption. Success depends not just on clinical efficacy, but on maintaining long-term engagement once a patient leaves the structured environment of a clinic. Furthermore, as the market for medical AI agents matures, Nyra Health faces the challenge of ensuring its pharmaceutical partnerships in the U.S. don’t overshadow its clinical independence, potentially turning a rehabilitation tool into a secondary support layer for drug manufacturers.
Key Details
- Funding: €20M (Series A)
- Lead: Armira Growth
- CEO: Moritz Schöllauf
- Sector: Digital Health / Neurorehabilitation
